Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricABVXAbivax SAGMABGenmab A/SINCYIncyte
Snapshot
Price$133.90$28.40$117.71
Market cap$11.63B$16.18B$23.35B
Valuation
P/E—20.9x16.5x
Forward P/E—27.9x11.8x
Growth
Revenue growth—20.7%21.5%
EPS growth—-25.3%2455.3%
Profitability
Net margin—21.1%26.7%
ROE-51.7%14.5%29.2%
Balance sheet & cash
Debt / equity0x0.93x0.01x
Free cash flow yield-2.1%—2.2%
Dividend yield———
Verdict
Investment ratingWeak· 35Favorable· 62Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearABVXtoday $134GMABtoday $28INCYtoday $118
2027$107.45 – $157.60+18% CAGR$21.73 – $31.86+12% CAGR$2,255.89 – $3,308.64+2711% CAGR
2028$114.98 – $168.63+12% CAGR$22.16 – $32.50+7% CAGR$57,645.02 – $84,546.03+2580% CAGR
2029$123.02 – $180.44+10% CAGR$22.60 – $33.15+5% CAGR$1,473,009.02 – $2,160,413.23+2538% CAGR
2030$131.64 – $193.07+10% CAGR$23.06 – $33.82+4% CAGR$37,639,946.83 – $55,205,255.35+2517% CAGR
2031$140.85 – $206.58+9% CAGR$23.52 – $34.49+4% CAGR$961,817,325.28 – $1,410,665,410.42+2504% CAGR
5-yr CAGR1.0% – 9.1%-3.7% – 4.0%2312.4% – 2504.5%